Orphenadrine Citrate Extended-Release Tablets Rx
Generic Name and Formulations:
Orphenadrine citrate 100mg; sust-rel tabs.
Various generic manufacturers
Indications for Orphenadrine Citrate Extended-Release Tablets:
Painful musculoskeletal conditions.
100mg twice daily (AM and PM).
Glaucoma. Achalasia. GU or GI obstruction. Myasthenia gravis.
Coronary disease, insufficiency, or arrhythmias. Asthma (inj). Monitor blood, urine, and liver in long-term use. Pregnancy (Cat.C). Nursing mothers.
Potentiates anticholinergics, alcohol, other CNS depressants, MAOIs, antidepressants. Tremors, mental confusion with propoxyphene. Antagonizes steroids, barbiturates, phenylbutazone.
Tachycardia, transient dizziness or syncope, other anticholinergic effects (eg, weakness, increased intraocular pressure, urinary retention, blurred vision, dry mouth), GI upset.
Formerly known under the brand name Norflex.
Norflex inj (YES)
Tabs—contact supplier; Amps (2mL)—6
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Nicotinamide and Cancer
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- Opioid Prescription Protocol Decreases Opioid Use After Gynecologic Surgery
- Everolimus Plus Letrozole May Be Active in Recurrent Endometrial Carcinoma
- Affordable Care Act Increased Percentage of Insured Patients With Gynecologic Cancers
- Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer
- FDA Approves Nilotinib for Pediatric Patients With CML